Glaucoma <\/a><\/strong>isn’t a single disease but a group of eye conditions that damage the optic nerve, typically due to elevated intraocular pressure (IOP). Often called\u00a0“the silent thief of sight,”<\/strong>\u00a0it can cause irreversible vision loss without noticeable symptoms until significant damage has occurred. Worldwide, glaucoma affects over 80 million people and is the\u00a0second leading cause of blindness<\/strong>, responsible for 12% of global blindness.<\/p>\n\n\n\n Your eye constantly produces a clear fluid called aqueous humor<\/strong>, which circulates through the anterior chamber<\/strong> before draining through a mesh-like structure called the trabecular meshwork<\/strong>. In healthy eyes, production and drainage maintain a delicate balance, keeping IOP between 10-21 mmHg<\/strong>.<\/p>\n\n\n\n Glaucoma develops when this drainage system becomes inefficient, causing fluid buildup and increased pressure. This elevated IOP compresses and damages the optic nerve<\/strong>\u2014the bundle of over one million nerve fibers transmitting visual information from the retina to the brain. The damage preferentially affects peripheral vision<\/strong> first, progressing inward toward central vision if untreated.<\/p>\n\n\n\n Characteristics:<\/strong>\u00a0The most common form (90% of cases in Western countries) develops slowly when the drainage angle remains\u00a0“open,”<\/strong>\u00a0but the trabecular meshwork becomes less efficient.<\/p>\n\n\n\n Risk Factors:<\/strong><\/p>\n\n\n\n Symptoms:<\/strong> None in early stages. By the time patients notice peripheral vision loss<\/strong>, significant optic nerve damage has already occurred.<\/p>\n\n\n\n Characteristics:<\/strong> Occurs when the iris<\/strong> physically blocks the drainage angle, causing sudden or gradual pressure buildup.<\/p>\n\n\n\n Acute Angle-Closure:<\/strong> Medical emergency with sudden symptoms:<\/p>\n\n\n\n Chronic Angle-Closure:<\/strong> Develops gradually, often asymptomatic until advanced.<\/p>\n\n\n\n Characteristics:<\/strong> Optic nerve damage occurs despite IOP measurements consistently within normal range<\/strong> (10-21 mmHg).<\/p>\n\n\n\n Theories:<\/strong> Possible causes include poor blood flow<\/strong> to the optic nerve, structural weakness, or increased sensitivity to normal pressure.<\/p>\n\n\n\n Caused by other conditions:<\/p>\n\n\n\n Rare forms present at birth or develop in childhood, often requiring surgical intervention.<\/p>\n\n\n\n Comprehensive glaucoma evaluation includes:<\/p>\n\n\n\n 1. Tonometry:<\/strong> Measures IOP using:<\/p>\n\n\n\n 2. Ophthalmoscopy:<\/strong> Direct examination of the optic nerve for cupping<\/strong> (enlargement of the central depression).<\/p>\n\n\n\n 3. Perimetry (Visual Field Test):<\/strong> Maps peripheral vision to detect characteristic patterns of loss.<\/p>\n\n\n\n 4. Gonioscopy:<\/strong> Uses a special lens to examine the drainage angle.<\/p>\n\n\n\n 5. Pachymetry:<\/strong> Measures corneal thickness<\/strong> (thinner corneas may underestimate true IOP).<\/p>\n\n\n\n 6. Optical Coherence Tomography (OCT):<\/strong> High-resolution imaging quantifies retinal nerve fiber layer thickness<\/strong>.<\/p>\n\n\n\n Screening Recommendations:<\/strong> Adults should have comprehensive eye exams:<\/p>\n\n\n\n While damaged optic nerve fibers cannot regenerate, current treatments effectively slow or halt progression by lowering IOP. The target pressure<\/strong> is individualized based on disease severity, with more aggressive lowering (30-50% reduction) needed for advanced damage.<\/p>\n\n\n\n Prostaglandin Analogs:<\/strong><\/p>\n\n\n\n Beta-Blockers:<\/strong><\/p>\n\n\n\n Alpha Agonists:<\/strong><\/p>\n\n\n\n Carbonic Anhydrase Inhibitors:<\/strong><\/p>\n\n\n\n Rho Kinase Inhibitors:<\/strong><\/p>\n\n\n\n Fixed-Combination Drugs:<\/strong> Simplify regimens (e.g., timolol-dorzolamide, brimonidine-brinzolamide).<\/p>\n\n\n\n Adherence Challenge:<\/strong> Approximately 50% of patients discontinue medications within 6 months due to cost, side effects, or complexity [4].<\/p>\n\n\n\n Selective Laser Trabeculoplasty (SLT):<\/strong><\/p>\n\n\n\n Laser Peripheral Iridotomy (LPI):<\/strong><\/p>\n\n\n\n Cyclophotocoagulation:<\/strong><\/p>\n\n\n\n Minimally Invasive Glaucoma Surgery (MIGS):<\/strong> Trabeculectomy:<\/strong><\/p>\n\n\n\n Tube Shunts:<\/strong><\/p>\n\n\n\n Cyclodestructive Procedures:<\/strong><\/p>\n\n\n\n Vision Rehabilitation:<\/strong> For those with vision loss:<\/p>\n\n\n\n Medication Management:<\/strong><\/p>\n\n\n\nUnderstanding the Mechanisms: How Glaucoma Damages Vision<\/strong><\/h3>\n\n\n\n
The Eye’s Plumbing System<\/strong><\/h4>\n\n\n\n
When the System Fails<\/strong><\/h4>\n\n\n\n
Types of Glaucoma: Not All Are Created Equal<\/a><\/strong><\/h3>\n\n\n\n
Primary Open-Angle Glaucoma (POAG)<\/strong><\/h4>\n\n\n\n
\n
Angle-Closure Glaucoma<\/a><\/strong><\/h4>\n\n\n\n
\n
Normal-Tension Glaucoma<\/a><\/strong><\/h4>\n\n\n\n
Secondary Glaucomas<\/a><\/strong><\/h4>\n\n\n\n
\n
Congenital and Juvenile Glaucomas<\/a><\/strong><\/h3>\n\n\n\n
Diagnosis: Catching the Thief Early<\/strong><\/h3>\n\n\n\n
\n
\n
Treatment Strategies: Lowering Pressure, Preserving Vision<\/h3>\n\n\n\n
Medications (First-Line Treatment)<\/strong><\/h4>\n\n\n\n
\n
\n
\n
\n
\n
Laser Therapies<\/strong><\/h4>\n\n\n\n
\n
\n
\n
Surgical Interventions<\/strong><\/h4>\n\n\n\n
Revolutionized surgical approach with better safety profiles:<\/p>\n\n\n\n\n
\n
\n
\n
Living with Glaucoma: Quality of Life and Adaptation<\/strong><\/h3>\n\n\n\n
\n
\n